【レポートの概要（一部）】
1. Report Overview
1.1 Brazil: Pharmaceutical Market Overview
1.2 Brazilian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Survey
1.6 Who is Our Report For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About Visiongain
2. Introduction to the Brazilian Pharmaceutical Market
2.1 The Brazilian Pharmaceutical Market Overview
2.2 Generics Segment Continues to Grow in Importance
2.3 CNS – The Largest Therapeutic Area in 2015
2.4 Four Domestic Companies in the Top Ten in 2015
3. The Significance of the Brazilian Market
3.1 Brazilian Economy is the Ninth Largest in the World
3.2 Brazil is the Eighth Largest Pharmaceutical Market
3.3 Brazil is the Largest Market in Latin America
3.4 Brazil Qualifies as a ‘Pharmerging’ Country and one of the BRIC Markets
4. Organisation of the Brazilian Pharmaceutical Market
4.1 ANVISA – Brazil’s Equivalent of the FDA
4.2 Other Influential Organisations
4.3 SUS – One of the World’s Largest Public Health Systems
4.4 Private Healthcare Accessed by 25% of the Population
4.5 Private Insurance Market Growing but Costs are Rising
4.6 New Drug Price Adjustment System Introduced
4.7 RENAME Drug Reimbursement System and the Farmácia Popular
4.8 Extensive Network of Pharmacies in Brazil
4.9 Wholesale and Retail Sectors Undergoing Consolidation
4.10 Panpharma is the Top Wholesale Distributor
4.11 Profarma is the Largest Mixed Distributor
4.12 Raia Drogasil is the Leader in the Retail Sector
4.13 Spending on Marketing Approaches $5bn
5. Major Differences in Healthcare Between Regions
5.1 Size and Prosperity of Different Regions
5.2 South-East is the Richest and Most Populous Region
5.3 South Has the Second Highest GDP
5.4 North-East Has the Second Highest Pharmaceutical Market Share
5.5 North is the Largest and Poorest Region
5.6 Mid-West is a Landlocked Region Housing the Nation’s Capital
6. Product Segments in the Brazilian Pharmaceutical Market 2016-2026
6.1 Forecasts for the Originator, Generic and OTC Segments 2015-2026
6.2 Originator Segment Will be Overtaken by Generics
6.2.1 Product Development Partnerships to Reduce Costs
6.2.2 Originator Drugs Threatened by 35% Cheaper Generics
6.3 Generics Drug Segment Forecast 2015-2026 – Continued Rapid Growth
6.3.1 Rapid Expansion of Generic Segment
6.3.2 Generic Companies Aiming for 45% Market Share
6.3.3 Similares Drugs Face Same Pricing Rules as Generics
6.3.4 Counterfeit Drugs Account for 20% of the Market
6.3.5 National Drug Security System to Tackle Counterfeit Drugs
6.3.6 Challenges for the Brazilian Generics Market
6.4 Brazilian Biologics Market
6.4.1 Biosimilars Market to Double in Size by 2017
6.4.2 BiocadBrazil Brings More Biosimilars to Brazil
6.5 OTC Drug Segment Forecast 2015-2026
6.5.1 Analgesics and Multivitamins Favoured by Brazilians
6.5.2 One Sixth of Population Buy Multivitamins
6.5.3 Restrictions on OTC Products Reversed
6.5.4 Consumer Health Treatments Remain Prominent in the Market
7. Therapeutic Areas of the Brazilian Market 2015-2026
7.1 Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2016
7.2 The Rise of Non-Communicable Diseases
7.3 Market Forecast for CNS Conditions 2015-2026
7.3.1 CNS Conditions Currently the Largest Therapeutic Area
7.3.2 Domestic Companies Target Generic and OTC CNS Products
7.3.3 Foreign Companies Target Analgesics Market
7.3.4 One Fifth of Brazilians Have Suffered Depression
7.3.5 CNS Conditions: Drivers and Restraints
7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2026
7.4.1 Rate of Cardiovascular Disease Expected to Triple
7.4.2 Almost One Quarter of the Population are Hypertensive
7.4.3 Statin Revenues Decline with Loss of Patent Protection
7.4.4 Domestic and International Companies Compete in CVS
7.4.5 Cardiovascular Opportunities and Challenges
7.5 Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2015-2026
7.5.1 High Prevalence of Diabetes and GI Conditions
7.5.2 Low Awareness of Diabetes Amongst Population
7.5.3 Drive for Domestic Production of Insulin
7.5.4 EMS’s Generic Esomeprazole an Important Addition
7.5.5 Capturing the Gastrointestinal/Metabolic Disease Opportunity
7.6 Market Forecast for Oncology Therapeutic Area, 2015-2026
7.6.1 Cancer Treatment to Become the Leading Therapeutic Area
7.6.2 Increased Coverage of Cancer Care by Private Health Insurance Providers
7.6.3 What are the Commonest Cancers in Brazil?
7.6.4 Biosimilars Will Help Widen Access to Cancer Drugs
7.6.5 Cristália and Libbs Amongst Leading Oncology Companies
7.6.6 Promising Potential of the Oncology Therapeutic Area
7.7 Market Forecast for Infectious Diseases Therapeutic Area, 2015-2026
7.7.1 Vaccines and Antibiotics Lead Therapeutic Area
7.7.2 Brazil Increasingly Manufacturing its Own Vaccines
7.7.3 First Vaccination Programme Against Dengue Fever
7.7.4 Free Access to HIV Care Despite Concerns About Patent Protection
7.7.5 Chagas Disease and Other Tropical Infections
7.7.6 Long-Term Threat From Zika Virus Epidemic
7.7.7 Importance of Infectious Diseases Compared to Chronic Diseases
7.8 Market Forecast for Other Therapeutic Areas, 2015-2026
8. Domestic Companies in the Brazilian Market
8.1 The Top Ten Domestic Pharmaceutical Companies in 2015
8.2 Multinational Companies Still Own the Majority of the Market
8.3 Domestic Sector Actively Encouraged by Government
8.4 Domestic Firms Control 70% of Generics Market
8.5 EMS: Brazil’s Leading Pharmaceutical Company
8.5.1 Separate Divisions for Different Drug Categories
8.5.2 Full Production and R&D Capability
8.5.3 Legrand and Germed are Key Subsidiaries
8.5.4 Targeted Expansion Overseas
8.6 Hypermarcas: Market Leader in OTC and Branded Generics
8.6.1 Neo Quimica: Ranked Third in the Generics Segment
8.6.2 Subsidiaries Include Mantecorp and Brainfarma
8.7 Medley: Generics Company Owned by Sanofi
8.8 Aché: A Major Acquisition Target in Brazil
8.8.1 Anti-Inflammatory Acheflan Was First Drug Developed in Brazil
8.8.2 Involvement of Aché in Acquisitions Process
8.8.3 Part of Bionovis Collaboration
8.9 Eurofarma: Fifth Largest Domestic Company with Plans to Cover 90% of Latin America
8.9.1 Policy to Make Acquisitions in Latin America
8.10 Teuto Operates Largest Pharmaceutical Complex in Latin America
8.10.1 Melcon Partnership and Other Growth Strategies for Teuto
8.11 Biolab Farmaceutica Leads Cardiology Drugs Market
8.11.1 Partnering With German and Indian Companies
8.11.2 Current Pipeline and Product Launches
8.12 Cristalia: Largest Producer of Anaesthetics in Latin America
8.12.1 Approval from ANVISA to Produce Biosimilar Drugs
8.12.2 Leader in API Manufacturing
8.12.3 Involved in One Third of all PDPs
8.13 Libbs: Key Player in Cancer Treatment
8.13.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
8.14 União Quimica: Huge Annual Production Capacity
8.14.1 Agreement with Novartis and Possible Public Offering in 2015
8.15 Other Domestic Players Include Laboratório Daudt Oliveira and Hebron
8.16 Biosimilar Collaborations
8.16.1 Bionovis: Conglomerate Developing 8 Biosimilars
8.16.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
8.16.3 Other Biotech Players Include Biomm and Innova
8.16.4 Fiocruz: At the Heart of Multiple PDPs
8.16.5 ANVISA Reform of Brazilian Patent System
9. Multinational Companies in the Brazilian Market
9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2015
9.2 Notable M&A Activity
9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
9.3.1 Group Companies Include Sanofi Pasteur and Genzyme
9.3.2 Inventory Mishandling and Dip in 2013 Results
9.4 Novartis: Only Multinational to Produce APIs in Brazil
9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
9.4.3 Investment in Expansion Plans
9.5 Roche: No Regrets About Staying in Brazil
9.5.1 Oncology Opportunity and Herceptin Pricing
9.6 Merck & Co. – Long-Standing Presence in the Brazilian Market
9.6.1 Five Factories and Five Broad Therapeutic Areas
9.6.2 Gardasil Added to SUS in 2013
9.6.3 Joint Venture with Eurofarma and Cristalia
9.7 Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers
9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
9.8 Takeda: Expanding its Brazilian Business
9.8.1 Acquisitions of Nycomed and Multilab
9.9 Bayer: Brazil is its Fifth Largest Market
9.9.1 OTC is a Major Focus in Brazil
9.10 AstraZeneca Targets Latin America
9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
9.11.1 Looking to Acquire OTC Brands
9.11.2 Technology Transfer Deal for Parkinson’s Disease
9.12 Merck KGaA Signed PDP with Bionovis for 8 Biosimilars
9.12.1 Two Divisions and Multiple Therapeutic Fields
9.13 Other Notable Multinationals in Brazil
9.13.1 GSK: Vaccines and Technology Transfer Opportunities
9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
9.13.3 Abbott: Generics and Diagnostics-Led Growth Strategy
9.13.4 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
9.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
9.13.6 Baxter Entering Haemophilia Market Via Technology Transfer
9.13.7 Johnson & Johnson: Focusing on Consumer Health and Commodities
9.13.8 BiocadBrazil Farmaceutica
9.13.9 Amgen Signals Brazilian Intent with Bergamo Acquisition
9.13.10 Gilead, Novo Nordisk, Biogen, UCB and Meizler
9.13.11 Other Top Japanese Companies Trail Behind Takeda in Brazil
9.14 Will Multinational Generics Leaders Compete in Brazil?
9.14.1 Teva Targets Brazil
9.14.2 Mylan Acquires Agila to Boost Brazilian Strategy
9.14.3 Actavis May Target Brazil
9.14.4 Ranbaxy and Daiichi Sankyo
9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
9.14.6 Valeant: M&A Drive Into the Market
9.15 Brazil as a Pharmaceutical Research Destination
10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2016
10.1 Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis
10.1.1 A Crucial Market for the Pharmaceutical Industry
10.1.2 Government Regulation Remains an Issue
10.1.3 One of the Highest Pharmaceutical Tax Rates in the World
10.1.4 Room to Expand in Therapeutic Areas and Geographic Regions
10.1.5 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
10.2 Social, Technological, Economic and Political (STEP) Analysis
10.2.1 Large and Ageing Population Eager to Buy Medicines
10.2.2 Shortcomings of Brazil’s Healthcare System
10.2.3 Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT
10.2.4 Can Economic Growth Keep Pace with Healthcare Costs?
10.2.5 Political Environment Acts as Decisive Influence on the Market
10.2.6 Will BREXIT Affect Free Trade Negotiations with the EU?
11. Research Interviews
11.1 Interview With Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
11.1.1 On Gaining Access to the Brazilian Market
11.1.2 Factors That Differentiate Brazil From Other Markets
11.1.3 The Brazilian Generics and Biosimilars Market and Biocad’s Progress with Biosimilars
11.1.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
11.1.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
11.1.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market and How the 2016 Olympics Will Compare
11.1.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses Will Improve in Coming Years
11.2 Interview with André Brazay, President of Sandoz Brazil
11.2.1 Impact of Current Political and Economic Situation
11.2.2 Challenges faced by Domestic Companies
11.2.3 How Generics Market in Brazil Differs from Other Countries
11.2.4 Importance of Biosimilars in Brazil
11.2.5 Factors for an Overseas Investor to Consider
11.2.6 Future Challenges for the Market in Brazil
12. Conclusions from Our Research and Analysis
12.1 Growth of Brazil’s Pharmaceutical Market Will Outstrip That of More Developed Countries
12.2 Generics Will be Major Driver of Growth
12.3 Technology Transfer Boosts Domestic Production of Originator Drugs
12.4 Generics Market Provides Alternative Option for Multinationals
12.5 Oncology is Leading Therapeutic and Commercial Opportunity
12.6 Concluding Comments
【レポート販売概要】
■ タイトル：医薬品のブラジル市場見通し2016-2026■ 英文：Brazilian Pharmaceutical Market Outlook 2016-2026
■ 発行日：2016年9月
■ 調査会社：visiongain
■ 商品コード：VGAIN60905
■ 調査対象地域：ブラジル
- 世界のスマートガラス市場動向及び予測2014 – 2020Smart glass is also known by switchable glass, dimmable glass or dynamic glass. It is a kind of glass which changes its light transmission properties according to the provided stimulus. Based on whether, they require an electrical stimulus to respond or the level of control it offers to users; it can be categorized into Active or Passive. Electrochromic, SPD, and Liquid crystal are some of the act …
- 次世代拡張現実アプリケーション（Next Generation Augmented Reality Applications）Augmented Reality (AR) represents a live, direct or indirect, view of a physical, real-world environment whose elements are augmented by computer-generated sensory input, that enrich the user's perception of the real world This research evaluates the potential for AR applications with a high benefit to society and those that go beyond the current commercial implementations. These so called next ge …
- Relentless Resources Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Relentless Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Relentless Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- 世界のファイバレーザ市場：用途別、地域別Global Fiber Laser Market: About this market Technavio’s fiber laser market analysis considers sales from material processing, advanced application, healthcare, and other applications. Our study also finds the sales of fiber laser in APAC, Europe, MEA, North America, and South America. In 2019, the material processing segment had a significant market share, and this trend is expected to continue o …
- アメリカの野球用品市場：野球バット、野球グラブ、野球シューズ、野球ボール、野球防具About Baseball Baseball was derived from bat-and-ball games which were played in the 1800s in England. This game was brought to America, where it was changed to its current version. The game has become so popular in the US that it has become the national sport. The US has the biggest professional baseball tournaments in the world. Professional baseball tournaments in the country are organized by M …
- 非侵襲的出生前検査の世界市場分析：妊娠期間別（0-12週、13-24週、25-36週）、妊娠リスクレベル別、（高リスク – 平均リスク、低リスク）、地域別（アメリカ、イギリス、ドイツ、日本、中国、ブラジル）、セグメント予測、2014-2025The global non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reprod …
- スマート発券の世界市場予測（～2022）：製品別 (発券機、Eチケット、Eキオスク）、構成要素別、システム別、用途別、地域別According to the MarketsandMarkets forecast, the smart ticketing market is expected be worth USD 10.22 Billion by 2022, growing at a CAGR of 7.93% between 2016 and 2022. The major drivers for the market include affordable access to smart transit system, emerging application travel and tourism industry, flourishing adoption of smart technology, and user-friendly platform. The report covers the smar …
- 消化酵素サプリメントの世界市場About Digestive Enzyme SupplementsDigestive enzymes are substances produced by a human body that aid in digestion of food. In cases of individuals, where there are insufficient enzymes, digestive enzyme supplements are consumed to assist digestion. Technavio’s analysts forecast the global digestive enzyme supplements market to grow at a CAGR of 5.23% during the period 2017-2021. [Covered in this r …
- サービスとしての生体認証の世界市場：コンポーネント別、組織規模別、モダリティ別、業種別Biometrics-as-a-Service is a centralized biometric database on the internet, which is used for authentication of a person based on a set of recognizable and verifiable data, which is unique and specific to them. The technology is considered widely useful as it lowers cost and helps customers to blend in different modalities to develop best use cases for different organizations and permit rapid int …
- 小腸結腸炎(Enterocolitis)：世界の治験レビュー（2015年上半期版）Enterocolitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Enterocolitis Global Clinical Trials Review, H1, 2015" provides data on the Enterocolitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Enterocolitis. It includes an overview of the trial numbers and their recruitment status as per the …
- 世界の膜分離活性汚泥法（MBR/排水処理システム）市場動向と予測The membrane bioreactor systems market size in terms of value is projected to grow at a CAGR of 15.28% between 2014 and 2019 to reach $2,927 million by 2019. Asia-Pacific held the largest share in 2013 with China leading the region. In low penetrated markets of Asia-Pacific and RoW, a high growth is expected while the highly developed North American and European regions are predicted to show a mod …
- スパウトパウチの世界市場2016-2020About Spout PouchConsidering consumer preferences, manufacturers are shifting from rigid packaging options that involve the use of materials such as glass and aluminum to more convenient and flexible packaging options to sustain growth and profitability. One such flexible packaging option is stand-up pouches. The demand for stand-up pouches is increasing due to innovations in their packaging style …
- うつ病治療薬の世界市場2015-2019About depression drugs According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly cat …
- 食品産業用パルス電場（PEF）システムの世界市場2020-2024Global Food Industry Pulsed Electric Field (PEF) Systems Market 2020-2024 Technavio has been monitoring the food industry pulsed electric field (PEF) systems market and it is poised to grow by USD 227.52 mn during 2020-2024, progressing at a CAGR of 24% during the forecast period. Our reports on food industry pulsed electric field (PEF) systems market provides a holistic analysis, market size and …
- ナノクレイの世界市場2010-2025Main end user markets for nanoclays are packaging, plastics, automotive and rheology modifiers. Secondary markets include academia and research, water filtration, flame retardant materials, medical and biomaterials and paints, pigments, coatings and dyes. This 41 page report from Future Markets, Inc. offers an in depth insight into the global nanoclays market including applications, markets and pr …
